{"analyses":[{"ciPctValue":"95","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.02","statisticalComment":"Model was stratified by beta-2 microglobulin (high vs low), lytic bone lesions (present vs not) and bone marrow labeling index (high vs low)","statisticalMethod":"Log Rank","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.4","upperLimit":"3.6","value":"2.4"},{"groupId":"OG001","lowerLimit":"0.7","upperLimit":"2.5","value":"1.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"33"}],"units":"Participants"}],"description":"Time to disease progression (TTP) was defined as the time from randomization to the earliest documentation of disease progression. Participants were followed for a maximum of 5 years from registration. The median OS with 95% CI was estimated using the Kaplan Meier method, a two-sided (stratified) log-rank test was calculated.","dispersionType":"95% Confidence Interval","groups":[{"description":"Thalidomide (Thal) + Zolendronic acid (ZLD)","id":"OG000","title":"Arm I: Thal/ZLD"},{"description":"Zoledronic acid (ZLD)","id":"OG001","title":"Arm II: ZLD"}],"paramType":"MEDIAN","populationDescription":"Time to disease progression was analyzed on all randomized participants on an intent to treat basis.","reportingStatus":"POSTED","timeFrame":"randomization to progression (up to 5 years)","title":"Time to Disease Progression (TTP)","type":"PRIMARY","unitOfMeasure":"years"}